Postmenopausal estrogen therapy: Which route to take?

Nature Clinical Practice Endocrinology and Metabolism

Volumn 5, Issue 3, 2009, Pages 146-147

  Simon, James A ^a,b,c  

^a GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

^b Women's Health and Research Consultants   (United States)

^c NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; CELL ADHESION MOLECULE; DYDROGESTERONE; ESTROGEN DERIVATIVE; GESTAGEN; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPOPROTEIN A; PROCOAGULANT; TRIACYLGLYCEROL; VITRONECTIN;

ABDOMINAL OBESITY; BREAST CANCER; COLORECTAL CANCER; ESTROGEN THERAPY; FEMALE; GALLBLADDER DISEASE; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN RESISTANCE; POSTMENOPAUSE; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; RISK REDUCTION; SHORT SURVEY; SIDE EFFECT; THROMBOEMBOLISM; THROMBOPHLEBITIS; THROMBOSIS; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 60749099832     PISSN: 17458366     EISSN: 17458374     Source Type: Journal    
DOI: 10.1038/ncpendmet1073     Document Type: Short Survey

References (10)

1. Modena MG et al. (2005) New evidence regarding hormone replacement therapies is urgently required transdermal postmenopausal hormone therapy differs from oral hormone therapy in risks and benefits. Maturitas 52: 1-10
2. L'Hermite M et al. (2008) Could transdermal estradiol + progesterone be a safer postmenopausal HRT? A review. Maturitas 60: 185-201
3. Slater CC et al. (2001) Markedly elevated levels of estrone sulfate after long-term oral, but not transdermal, administration of estradiol in postmenopausal women. Menopause 8: 200-203
4. Arafah BM (2001) Increased need for thyroxine in women with hypothyroidism during estrogen therapy. N Engl J Med 344: 1743-1749
5. Canonico M et al. (2008) Hormone replacement therapy and risk of venous thromboembolism in postmenopausal women: systematic review and meta-analysis. BMJ 336: 1227-1231
6. Salpeter SR et al. (2006) Meta-analysis: effect of hormone-replacement therapy on components of the metabolic syndrome in postmenopausal women. Diabetes Obes Metab 8: 538-554
7. Løkkegaard E et al. (2008) Hormone therapy and risk of myocardial infarction: a national register study. Eur Heart J 29: 2660-2668
8. Liu B et al. (2008) Gallbladder disease and use of transdermal versus oral hormone replacement therapy in postmenopausal women: prospective cohort study. BMJ 337: a386
9. Fournier A et al. (2008) Unequal risks for breast cancer associated with different hormone replacement therapies: results from the E3N cohort study. Breast Cancer Res Treat 107: 103-111
10. Csizmadi I et al. (2004) The effects of transdermal and oral oestrogen replacement therapy on colorectal cancer risk in postmenopausal women. Br J Cancer 90: 76-81